Table 3.
ERCC2 Asp312Asn, ERCC2 Lys751Gln polymorphisms and potential breast cancer risk factors
| Nonsmokers | Smokers | |||||||
| Genotype | Cases (%) | Controls (%) | OR (CI 95%) | P value | Cases (%) | Controls (%) | OR (CI 95%) | P value |
| ERCC2 Asp312Asn | ||||||||
| Asp/Asp | 283 (45) | 299 (47) | 1.00 (reference) | 102 (42) | 159 (44) | 1.00 (reference) | ||
| Asp/Asn | 258 (41) | 270 (43) | 1.01 (0.80–1.28) | 111 (46) | 146 (41) | 1.19 (0.83–1.68) | ||
| Asn/Asn | 85 (14) | 64 (10) | 1.4 (0.98–2.02) | 0.16 | 29 (12) | 54 (15) | 0.84 (0.50–1.40) | 0.36 |
| No HRT* users | HRT users | |||||||
| Genotype | Cases (%) | Controls (%) | OR (CI 95%) | P value | Cases (%) | Controls (%) | OR (CI 95%) | P value |
| ERCC2 Asp312Asn | ||||||||
| Asp/Asp | 175 (46) | 137 (48) | 1.00 (reference) | 75 (40) | 216 (47) | 1.00 (reference) | ||
| Asp/Asn | 152 (40) | 119 (41) | 1.00 (0.72–1.39) | 92 (49) | 191 (42) | 1.39 (0.97–1.99) | ||
| Asn/Asn | 54 (14) | 31 (11) | 1.36 (0.83–2.23) | 0.44 | 19 (10) | 50 (11) | 1.09 (0.61–1.97) | 0.20 |
| No OC** users | OC users | |||||||
| Genotype | Cases (%) | Controls (%) | OR (CI 95%) | P value | Cases (%) | Controls (%) | OR (CI 95%) | P value |
| ERCC2 Asp312Asn | ||||||||
| Asp/Asp | 240 (46) | 215 (50) | 1.00 (reference) | 143 (42) | 243 (43) | 1.00 (reference) | ||
| Asp/Asn | 208 (40) | 176 (41) | 1.06 (0.81–1.39) | 161 (47) | 242 (43) | 1.13 (0.85–1.51) | ||
| Asn/Asn | 74 (14) | 40 (9) | 1.66 (1.08–2.53) | 0.061 | 40 (12) | 78 (14) | 0.87 (0.56–1.34) | 0.44 |
| ERCC2 Lys751Gln | ||||||||
| Lys/Lys | 79 (15) | 39 (9) | 1.00 (reference) | 38 (11) | 80 (14) | 1.00 (reference) | ||
| Lys/Gln | 223 (43) | 198 (46) | 0.56 (0.36–0.85) | 181 (52) | 248 (44) | 1.54 (1.00–2.36) | ||
| Gln/Gln | 222 (42) | 195 (45) | 0.56 (0.37–0.86) | 0.018 | 127 (37) | 235 (42) | 1.14 (0.73–1.77) | 0.044 |
| Age at first OC use ≤ 23 years | Age at first OC > 23 years | |||||||
| Genotype | Cases (%) | Controls (%) | OR (CI 95%) | P value | Cases (%) | Controls (%) | OR (CI 95%) | P value |
| ERCC2 Lys751Gln | ||||||||
| Lys/Lys | 23 (14) | 46 (15) | 1.00 (reference) | 15 (8) | 34 (13) | 1.00 (reference) | ||
| Lys/Gln | 80 (50) | 145 (47) | 1.10 (0.62–1.95) | 101 (55) | 103 (40) | 2.22 (1.15–4.29) | ||
| Gln/Gln | 58 (36) | 115 (38) | 1.01 (0.56–1.82) | 0.89 | 69 (37) | 120 (47) | 1.3 (0.66–2.56) | 0.008 |
| Waist-to-hip ratio = 0.85 | Waist-to-hip ratio > 0.85 | |||||||
| Genotype | Cases (%) | Controls (%) | OR (CI 95%) | P value | Cases (%) | Controls (%) | OR (CI 95%) | P value |
| ERCC2 Asp312Asn | ||||||||
| Asp/Asp | 252 (46) | 356 (46) | 1.00 (reference) | 151 (42) | 102 (48) | 1.00 (reference) | ||
| Asp/Asn | 234 (43) | 326 (42) | 1.01 (0.80–1.28) | 149 (42) | 92 (43) | 1.09 (0.76–1.57) | ||
| Asn/Asn | 60 (11) | 98 (13) | 0.86 (0.60–1.24) | 0.68 | 58 (16) | 20 (9) | 1.96 (1.12–3.43) | 0.06 |
* HRT = Hormone Replacement Therapy
** OC = Oral Contraceptive